Lithuania Pharmaceuticals and Healthcare Report Q1 2013

Publisher Name :
Date: 16-Jan-2013
No. of pages: 96

We continue to hold our subdued outlook for the Lithuanian pharmaceuticals market during the next few years, on account of the changing economic and demographic situation. We expect limited low single digit growth in 2012, with the market expected to increase by a local currency margin of 2.5 %year-on-year (y-o-y) to reach LTL1.68bn (US$618mn) in 2012 at consumer prices. However, in US dollar terms, the market’s value will shrink by 6.3%, indicating the challenges facing companies operating in the market.

Headline Expenditure Projections

  • Pharmaceuticals:LTL1.64bn (US$659mn) in 2011 to LTL1.68bn (US$618mn) in 2012; +2.5 %in local currency terms and -6.3% in US dollar terms. Forecast slightly up from Q412 on account of new macroeconomic data.
  • Healthcare:LTL6.99bn (US$2.81bn) in 2011 to LTL7.29bn (US$2.68bn) in 2012; +4.3% in local currency terms and -4.7% in US dollar terms. Forecast slightly up from Q412 on account of new macroeconomic data.
  • Medical devices:LTL679mn (US$273mn) in 2011 to LTL749mn (US$276mn) in 2012; +10.3% in local currency terms and +0.8% in US dollar terms. Forecast slightly up from Q412 on account of new macroeconomic data.

Risk/Reward Rating:

In our Q113 Pharmaceuticals Risk/Reward Rating (RRR) matrix, Lithuania is 15th, out of the 20 markets surveyed in Emerging Europe, below its Baltic peers. Although Lithuania boasts a largely risk-free operating environment, its muted rewards prospects will continue to impact its standing in the regional matrix. Globally, Lithuania ranks 60th out of 95 markets surveyed.

Key Trends and Developments

In October 2012, Seimas of the Homeland Union-Lithuanian Christian Democrats (TS-LKD) faction George Razma appealed the government to reconsider additional funding of LTL60.0mn (US$22.7mn) for healthcare institutions in the country. Lithuanian patients have to pay extra for medical services that should be available for free, Razma said. The additional funds are expected to partially solve the issue of lack of funding for treatment services. Razma asked the government to evaluate the proposal after considering the difficult situation of Lithuania’s hospital system.

BMI Economic View:

We have revised up our growth outlook for 2013 economic growth on account of improved financing conditions and signs of a tightening labour market. However, Lithuania’s construction sector remains a long way off from a meaningful recovery, and coupled with a weak external climate, we maintain a tepid outlook for the economy over the coming years.

BMI Political View:

Controversy surrounding an ongoing criminal investigation into key members of a majority newly-elected coalition party means that the incoming administration of Prime Ministerdesignate Algirdas Butkevicius will be under enormous pressure to acquire political credibility by honouring its anti-austerity mandate. Although we have long accounted for a looser fiscal policy in our view that Lithuania would continue to progress towards euro adoption, the risk of major coalition instability and a rift with the president’s office threatens to force the government into a far more aggressive policy direction than under our current baseline scenario.

Lithuania Pharmaceuticals and Healthcare Report Q1 2013

Table of Contents

Executive Summary  6
SWOT Analysis  8
Lithuania Pharmaceuticals And Healthcare Industry SWOT  8
Lithuania Political SWOT  9
Lithuania Economic SWOT  9
Lithuania Business Environment SWOT  10
Pharmaceuticals Risk/Reward Ratings  11
Table: Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings, Q113  11
Rewards  12
Risks  12
Lithuania - Market Summary  14
Regulatory Regime  15
Regional Harmonisation  16
Pharmaceutical Advertising  17
Intellectual Property Developments  18
Pricing Regime  19
Pricing Developments  20
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines 22
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines 23
Reimbursement Regime  23
Reimbursement Developments  24
Industry Developments 26
Epidemiology  26
Table: Leading Causes of Death, 2002-2010  27
Communicable Diseases  27
Table: Selected Notifiable Infectious Diseases, 2004-2010 28
Table: Incidence of HIV & AIDS, 2002-2010  29
Healthcare System  29
Healthcare Provision  29
Table: Inpatient Institutions & Hospital Beds by Sector, 2000-2010  30
Table: Outpatient Facilities by Type, 2003-2010  30
Healthcare Funding  31
Healthcare Insurance  32
E-Health  32
Clinical Trials  33
Biotechnology  34
Recent Biotechnology Sector Developments  35
Medical Devices 36
Industry Forecast Scenario  37
Pharmaceutical Market Forecast  37
Table: Pharmaceutical Sales Indicators 2008-2016  38
Healthcare Market Forecast  39
Table: Healthcare Expenditure Indicators 2008-2016  40
Table: Healthcare Governmental Indicators 2008-2016  41
Table: Healthcare Private Indicators 2008-2016  41
Key Growth Factors - Macroeconomic  42
Table: Economic Activity  51
Prescription Drug Market Forecast  52
Table: Prescription Drug Sales Indicators 2008-2016  54
Patented Drug Market Forecast  55
Table: Patented Drug Market Indicators 2008-2016  56
Generic Drug Market Forecast  57
Table: Generic Drug Sales Indicators 2008-2016  58
OTC Medicine Market Forecast  59
Table: OTC Medicine Sales Indicators 2008-2016  60
Pharmaceuticals Trade Forecast 61
Table: Exports and Imports Indicators 2008-2016  62
Medical Device Market Forecast 63
Table: Medical Devices Sales Indicators 2008-2016  63
Key Risks To BMI's Forecast Scenario  64
Competitive Landscape  65
Pharmaceuticals Sector 65
Table: Members of the Association of Manufacturers of Drugs (VGA), 2011  65
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA)  66
Domestic Industry  66
Pharmaceutical Wholesale  67
Pharmaceutical Retail  68
Table: Pharmacies, 2000-2010  69
Pharmaceutical Distribution Developments  70
Company Profiles  72
Local Companies  72
Valentis  72
Sanitas (Valeant)  74
Sicor Biotech (Teva)  77
Multinational Companies  79
GlaxoSmithKline  79
Pfizer 81
Novartis  82
Merck & Co  83
Sanofi 84
Demographic Outlook  85
Table: Lithuania's Population By Age Group, 1990-2020 ('000)  86
Table: Lithuania's Population By Age Group, 1990-2020 (% of total) 87
Table: Lithuania's Key Population Ratios, 1990-2020  88
Table: Lithuania's Rural And Urban Population, 1990-2020 88
Glossary  89
BMI Methodology  91
How We Generate Our Pharmaceuticals Industry Forecasts 91
Pharmaceuticals Risk/Reward Ratings Methodology 92
Ratings Overview  92
Table: Pharmaceutical Business Environment Indicators  93
Weighting  94
Table: Weighting Of Components  94

List of Tables

Table: Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings, Q113
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines
Table: Leading Causes of Death, 2002-2010
Table: Selected Notifiable Infectious Diseases, 2004-2010
Table: Incidence of HIV & AIDS, 2002-2010
Table: Inpatient Institutions & Hospital Beds by Sector, 2000-2010
Table: Outpatient Facilities by Type, 2003-2010
Table: Pharmaceutical Sales Indicators 2008-2016
Table: Healthcare Expenditure Indicators 2008-2016
Table: Healthcare Governmental Indicators 2008-2016
Table: Healthcare Private Indicators 2008-2016
Table: Economic Activity
Table: Prescription Drug Sales Indicators 2008-2016
Table: Patented Drug Market Indicators 2008-2016
Table: Generic Drug Sales Indicators 2008-2016
Table: OTC Medicine Sales Indicators 2008-2016
Table: Exports and Imports Indicators 2008-2016
Table: Medical Devices Sales Indicators 2008-2016
Table: Members of the Association of Manufacturers of Drugs (VGA), 2011
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA)
Table: Pharmacies, 2000-2010
Table: Lithuania's Population By Age Group, 1990-2020 ('000)
Table: Lithuania's Population By Age Group, 1990-2020 (% of total)
Table: Lithuania's Key Population Ratios, 1990-2020
Table: Lithuania's Rural And Urban Population, 1990-2020
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Growth in the Indian Watch Industry
    Earlier, in India watches were seen as a luxury item. However, watches are now witnessing a fundamental change in perception, and are now gaining respect as an essential utility item. With the liberalization of the Indian market, coupled with the rising purchasing power of the young and consumerist Indians, watch industry in India seems to [...]
  • Global Retail Ready Packaging Market to Witness Steady Growth
    The market for retail ready packaging has witnessed impressive growth in recent years with boom in the retail industry. Retail ready packaging, also known as shelf-ready packaging is designed for the retail outlet, ready to be placed on shelf without any need for unpacking or repacking. In 2011, the global market for retail packaging was [...]
  • Denmark Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 60
    BMI View: Although Denmark's pharmaceutical market is relatively small compared to other Western European countries, the demand for high quality healthcare will remain elevated by an increasing and ageing population. This demand could provide opportunities for private healthcare providers to expand as the government continues its restructuring and cost containment measures across the public healthcare sector. Headline Expenditure Projections ? Pharmaceuticals: DKK20.20bn (US$3.58bn) in 2013 to D......
  • Iraq Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 75
    BMI View: The projected growth of Iraq's pharmaceutical market in 2014 and 2015 is linked to an oildriven economic expansion, which is dependent on the government's ability to represent and appease the country's factions. Given the government's expansionary fiscal policy, spending on education, health and public services will be elevated over the coming quarters. In particular, Baghdad will seek to modernise healthcare provision, in a view to improve support to its rule. Nevertheless, there are ......
  • Lithuania Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 98
    BMI View: We expect the Lithuanian pharmaceutical market to post a five-year compound annual growth rate (CAGR) of 4.4%, rising to a value of LTL2.16bn (US$751mn) in 2018. While double-digit annual growth rates are firmly in the past, some opportunities continue to exist in light of epidemiological factors and an ageing population. The upcoming switch to the euro promises to boost purchasing power and stabilise the pharmaceutical market. However, the Lithuanian market will continue to represent ......
  • Sri Lanka Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 78
    BMI View: A better-than-expected outlook for Sri Lanka's economy has led us to upwardly revise our pharmaceutical and healthcare forecasts. The government has introduced price controls on wholesale and retail prices of imported drugs, which will limit trade. However, the government's focus on imports of lowcost drugs directly from the governments of Bangladesh and Thailand, using the state pharmaceutical corporation, will limit dependency on Indian exporters. Furthermore, the government's streng......
  • Venezuela Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 126
    BMI View: Foreign currency controls and drug price cuts will continue to affect pharmaceutical companies' profitability, with the currency devaluation and high inflation exacerbating the situation. A close relationship and effective communication with the Venezuelan government are vital for the survival of domestic pharmaceutical companies. As the Venezuelan government tries to increase access to medicines, more co-ordination with drug producers to address these issues will become necessary. Hea......
  • Bahrain Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 101
    BMI View: This quarter has seen the beginning of a multi-phased plan by the National Health Regulatory Authority to significantly reduce medicine prices in the country, signalling a potential advancement towards the implementation of a unified Gulf Cooperation Council pricing system. Although less optimistic than before, our medium- and long-term outlooks for the Bahrain pharmaceutical market remain bullish. Medicines uptake will be supported by robust economic growth, in addition to the country......
  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 65
    BMI View: Low health and pharmaceutical expenditures will continue to limit the attractiveness of the pharmaceutical market in Cambodia. Given such a profile, the country will present more commercial benefits to companies dealing with inexpensive generic drugs and over-the-counter products than innovative pharmaceuticals. Headline Expenditure Projections ? Pharmaceuticals: KHR828.7bn (US$210mn) in 2013 to KHR921.9bn (US$230mn) in 2014; +11.2% in local currency terms and +11.8% in US dollar terms......
  • Morocco Pharmaceuticals and Healthcare Report Q2 2014
    Published: 9-Apr-2014        Price: US $1295 Onwards        Pages: 112
    BMI View: We expect poor economic conditions in Morocco will lead to continuing decline in pharmaceutical imports and spending in the short term. However, the rate of decline in pharmaceutical sales is starting to slow, indicating that conditions for Moroccan drugmakers are beginning to improve as the growing middle class drives demand. Our outlook is therefore more positive over the long term. Meanwhile, the patented drugs market will continue to take the largest percentage of overall pharmaceu......
  • Saudi Arabia Pharmaceuticals and Healthcare Report Q2 2014
    Published: 9-Apr-2014        Price: US $1295 Onwards        Pages: 119
    BMI View: We hold a very positive outlook towards growth in the Saudi Arabian medicines market over the next decade, with pharmaceutical demand underpinned by a number of factors. However, risks to our outlook are to the downside, some of which include greater-than-expected drops in the oil price, the government's failure to deliver on healthcare infrastructure expansion and medicine price cuts in the short term. Headline Expenditure Projections ? Pharmaceuticals: SAR22.7bn (US$6.06bn) in 2013 t......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs